Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrelizumab plus radiotherapy and chemotherapy for recurrent or metastatic cervical cancer (Phase II, single-arm)
ChiCTR2000041564Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in cervical cancer (mCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective response rate. Started Jan 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
cervical cancer (mCC)
Beyond the preview
Go deeper on ChiCTR2000041564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041564.